{"id":68384,"date":"2018-03-01T19:16:55","date_gmt":"2018-03-02T01:16:55","guid":{"rendered":"http:\/\/news.medill.northwestern.edu\/chicago\/?p=68384"},"modified":"2018-03-01T19:16:55","modified_gmt":"2018-03-02T01:16:55","slug":"abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic","status":"publish","type":"post","link":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/","title":{"rendered":"Abbott buys rights to a vascular balloon, possibly confronting Medtronic"},"content":{"rendered":"

Roxanne (Yanchun) Liu<\/strong>
\nMedill Reports<\/em><\/p>\n

Illinois-based healthcare giant Abbott Laboratories (NYSE:\u00a0ABT) announced Tuesday that it would pay up to $92 million to secure global commercialization rights for SurVeil, a Minnesota company’s drug-coated vascular balloon designed to treat peripheral artery disease, or PAD, a niche market already occupied by muscular competitors including Medtronic PLC (NYSE: MDT).<\/p>\n

The worldwide peripheral vascular devices market is estimated to surge to $12.63 billion by 2022 from $9.09 billion in 2017, according to a report by Research and Markets. The drug-coated balloon, also known as a drug-eluting balloon, is an alternative therapy to the market-dominating drug-coated stents. SurVeil, currently in clinical trials, would be the first PAD-targeted drug-coated balloon in Abbott\u2019s portfolio.<\/p>\n

SurVeil\u2019s developer, medical device company Surmodics Inc. (NASDAQ: SRDX), has been conducting a pivotal clinical trial that tests the new device against the In.PACT Admiral drug-coated balloon, the current U.S. market-leading product manufactured by Minnesota-based Medtronic, one of the major rivals of Abbott in vascular care.<\/p>\n

<\/p>\n

SurVeil needs to yield strong clinical profile in order to help Abbott wrestle with Medtronic, RBC Capital Markets analyst Glenn Novarro said.<\/p>\n

\u201cBeing so late to the game, the clinical data [of SurVeil] would have to be very competitive,\u201d Novarro said, citing the at-least-three-year process of getting approval from the U.S. Food and Drug Administration.<\/p>\n

The prospect of drug-coated balloon technology in the field of peripheral interventions means that Abbott also has to race with other major biotech players.<\/p>\n

Massachusetts-based Boston Scientific Corp. (NYSE: BSX) announced in early February its intention to roll out its Ranger paclitaxel-coated balloon to the U.S. market in 2020. The company claimed in its first-quarter earnings report that Ranger has demonstrated in a recent trial similar performance to Medtronic\u2019s In.PACT Admiral in reducing vessel blockage.<\/p>\n

International capital also has added fuel to the competition. Netherlands-based Koninklijke Philips N.V. (NYSE: PHG) closed a $2.2 billion deal in August to buy Spectranetics Corp. (NASDAQ: SPNC), shortly after the Colorado-based vascular intervention device manufacturer announced receipt of FDA pre-market approval of its Stellarex drug-coated balloon.<\/p>\n

The Dutch company\u2019s primary objective of the acquisition was to get control of Spectranetics\u2019 drug-coated balloon, Lake Street Capital Markets analyst Brooks O’Neil said.<\/p>\n

\u201cPhilips paid $2.2 billion for a drug-eluting balloon that hasn\u2019t been tested against the market-leading product,\u201d O’Neil said. \u201cThe implication of Surmodics testing their product against Medtronic\u2019s product is, pretty clear we believe, Surmodics\u2019 product is superior.\u201d<\/p>\n

Abbott said in a press release that SurVeil\u2019s “Pre-clinical data showed a three- to five-times higher target tissue drug concentration, a more evenly distributed and durable drug effect, and lower incidence of downstream drug particles compared to the control drug-coated balloon.”<\/p>\n

Abbott agreed to an initial payment to Surmodics of $25 million and additions of as much as $67 million for product development milestones, the company said in a press release.<\/p>\n

Abbott also received options to negotiate pacts for Surmodics’ pipeline products, including below-the-knee and arteriovenous fistula drug-coated balloon devices that are in pre-clinical development, Abbott said.<\/p>\n

Shares of Surmodics jumped 9.74 percent to $29.85 on Tuesday, up $2.65.<\/p>\n

Photo at top: The logo of Abbott Laboratories, Illinois-based broad range healthcare corporation. (Abbott)<\/div>\n","protected":false},"excerpt":{"rendered":"

Roxanne (Yanchun) Liu Medill Reports Illinois-based healthcare giant Abbott Laboratories (NYSE:\u00a0ABT) announced Tuesday that it would pay up to $92 million to secure global commercialization rights for SurVeil, a Minnesota company’s drug-coated vascular balloon designed to treat peripheral artery disease, or PAD, a niche market already occupied by muscular competitors including Medtronic PLC (NYSE: MDT). […]<\/p>\n","protected":false},"author":449,"featured_media":68401,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27,3987],"tags":[],"class_list":["post-68384","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-winter-2018"],"yoast_head":"\nAbbott buys rights to a vascular balloon, possibly confronting Medtronic - Medill Reports Chicago<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott buys rights to a vascular balloon, possibly confronting Medtronic - Medill Reports Chicago\" \/>\n<meta property=\"og:description\" content=\"Roxanne (Yanchun) Liu Medill Reports Illinois-based healthcare giant Abbott Laboratories (NYSE:\u00a0ABT) announced Tuesday that it would pay up to $92 million to secure global commercialization rights for SurVeil, a Minnesota company’s drug-coated vascular balloon designed to treat peripheral artery disease, or PAD, a niche market already occupied by muscular competitors including Medtronic PLC (NYSE: MDT). […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/\" \/>\n<meta property=\"og:site_name\" content=\"Medill Reports Chicago\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-02T01:16:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.amazonaws.com\/medill.wordpress.offload\/WP%20Media%20Folder%20-%20medill-reports-chicago\/wp-content\/uploads\/sites\/3\/2018\/03\/ABBOTT-LOGO.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"470\" \/>\n\t<meta property=\"og:image:height\" content=\"511\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"yanchunliu2017\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"yanchunliu2017\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/\"},\"author\":{\"name\":\"yanchunliu2017\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/#\\\/schema\\\/person\\\/6619104b8c38093d46494802cc12605d\"},\"headline\":\"Abbott buys rights to a vascular balloon, possibly confronting Medtronic\",\"datePublished\":\"2018-03-02T01:16:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/\"},\"wordCount\":537,\"image\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.amazonaws.com\\\/medill.wordpress.offload\\\/WP%20Media%20Folder%20-%20medill-reports-chicago\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2018\\\/03\\\/ABBOTT-LOGO.jpg\",\"articleSection\":[\"Business\",\"Winter 2018\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/\",\"url\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/\",\"name\":\"Abbott buys rights to a vascular balloon, possibly confronting Medtronic - Medill Reports Chicago\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.amazonaws.com\\\/medill.wordpress.offload\\\/WP%20Media%20Folder%20-%20medill-reports-chicago\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2018\\\/03\\\/ABBOTT-LOGO.jpg\",\"datePublished\":\"2018-03-02T01:16:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/#\\\/schema\\\/person\\\/6619104b8c38093d46494802cc12605d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.amazonaws.com\\\/medill.wordpress.offload\\\/WP%20Media%20Folder%20-%20medill-reports-chicago\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2018\\\/03\\\/ABBOTT-LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/s3.amazonaws.com\\\/medill.wordpress.offload\\\/WP%20Media%20Folder%20-%20medill-reports-chicago\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2018\\\/03\\\/ABBOTT-LOGO.jpg\",\"width\":470,\"height\":511,\"caption\":\"Abbott is an Illinois-based health care giant.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott buys rights to a vascular balloon, possibly confronting Medtronic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/#website\",\"url\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/\",\"name\":\"Medill Reports Chicago\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/#\\\/schema\\\/person\\\/6619104b8c38093d46494802cc12605d\",\"name\":\"yanchunliu2017\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4e988783a7e403eaabc94e97c0e0f967fe3825babb093530d475dce3401c0dbd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4e988783a7e403eaabc94e97c0e0f967fe3825babb093530d475dce3401c0dbd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4e988783a7e403eaabc94e97c0e0f967fe3825babb093530d475dce3401c0dbd?s=96&d=mm&r=g\",\"caption\":\"yanchunliu2017\"},\"url\":\"https:\\\/\\\/news.medill.northwestern.edu\\\/chicago\\\/author\\\/yanchunliu2017\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abbott buys rights to a vascular balloon, possibly confronting Medtronic - Medill Reports Chicago","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/","og_locale":"en_US","og_type":"article","og_title":"Abbott buys rights to a vascular balloon, possibly confronting Medtronic - Medill Reports Chicago","og_description":"Roxanne (Yanchun) Liu Medill Reports Illinois-based healthcare giant Abbott Laboratories (NYSE:\u00a0ABT) announced Tuesday that it would pay up to $92 million to secure global commercialization rights for SurVeil, a Minnesota company’s drug-coated vascular balloon designed to treat peripheral artery disease, or PAD, a niche market already occupied by muscular competitors including Medtronic PLC (NYSE: MDT). […]","og_url":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/","og_site_name":"Medill Reports Chicago","article_published_time":"2018-03-02T01:16:55+00:00","og_image":[{"width":470,"height":511,"url":"https:\/\/s3.amazonaws.com\/medill.wordpress.offload\/WP%20Media%20Folder%20-%20medill-reports-chicago\/wp-content\/uploads\/sites\/3\/2018\/03\/ABBOTT-LOGO.jpg","type":"image\/jpeg"}],"author":"yanchunliu2017","twitter_card":"summary_large_image","twitter_misc":{"Written by":"yanchunliu2017","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#article","isPartOf":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/"},"author":{"name":"yanchunliu2017","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/#\/schema\/person\/6619104b8c38093d46494802cc12605d"},"headline":"Abbott buys rights to a vascular balloon, possibly confronting Medtronic","datePublished":"2018-03-02T01:16:55+00:00","mainEntityOfPage":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/"},"wordCount":537,"image":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.amazonaws.com\/medill.wordpress.offload\/WP%20Media%20Folder%20-%20medill-reports-chicago\/wp-content\/uploads\/sites\/3\/2018\/03\/ABBOTT-LOGO.jpg","articleSection":["Business","Winter 2018"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/","url":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/","name":"Abbott buys rights to a vascular balloon, possibly confronting Medtronic - Medill Reports Chicago","isPartOf":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/#website"},"primaryImageOfPage":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#primaryimage"},"image":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.amazonaws.com\/medill.wordpress.offload\/WP%20Media%20Folder%20-%20medill-reports-chicago\/wp-content\/uploads\/sites\/3\/2018\/03\/ABBOTT-LOGO.jpg","datePublished":"2018-03-02T01:16:55+00:00","author":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/#\/schema\/person\/6619104b8c38093d46494802cc12605d"},"breadcrumb":{"@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#primaryimage","url":"https:\/\/s3.amazonaws.com\/medill.wordpress.offload\/WP%20Media%20Folder%20-%20medill-reports-chicago\/wp-content\/uploads\/sites\/3\/2018\/03\/ABBOTT-LOGO.jpg","contentUrl":"https:\/\/s3.amazonaws.com\/medill.wordpress.offload\/WP%20Media%20Folder%20-%20medill-reports-chicago\/wp-content\/uploads\/sites\/3\/2018\/03\/ABBOTT-LOGO.jpg","width":470,"height":511,"caption":"Abbott is an Illinois-based health care giant."},{"@type":"BreadcrumbList","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/abbott-buys-rights-to-a-vascular-balloon-possibly-confronting-medtronic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/news.medill.northwestern.edu\/chicago\/"},{"@type":"ListItem","position":2,"name":"Abbott buys rights to a vascular balloon, possibly confronting Medtronic"}]},{"@type":"WebSite","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/#website","url":"https:\/\/news.medill.northwestern.edu\/chicago\/","name":"Medill Reports Chicago","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/news.medill.northwestern.edu\/chicago\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/news.medill.northwestern.edu\/chicago\/#\/schema\/person\/6619104b8c38093d46494802cc12605d","name":"yanchunliu2017","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4e988783a7e403eaabc94e97c0e0f967fe3825babb093530d475dce3401c0dbd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4e988783a7e403eaabc94e97c0e0f967fe3825babb093530d475dce3401c0dbd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4e988783a7e403eaabc94e97c0e0f967fe3825babb093530d475dce3401c0dbd?s=96&d=mm&r=g","caption":"yanchunliu2017"},"url":"https:\/\/news.medill.northwestern.edu\/chicago\/author\/yanchunliu2017\/"}]}},"_links":{"self":[{"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/posts\/68384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/users\/449"}],"replies":[{"embeddable":true,"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/comments?post=68384"}],"version-history":[{"count":0,"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/posts\/68384\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/media\/68401"}],"wp:attachment":[{"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/media?parent=68384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/categories?post=68384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.medill.northwestern.edu\/chicago\/wp-json\/wp\/v2\/tags?post=68384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}